EUVIMEDEUVIMED entdecken
Crossref

Characterization of SF3B1 role in prolactin-secreting pituitary tumors

Federica Mangili iD, Anna Maria Barbieri, Genesio Di Muro, Emanuela Esposito, Donatella Treppiedi iD, Marco Locatelli, Andrea G Lania, Márta Korbonits iD, Erika Peverelli iD, Giovanna Mantovani

Endocrine-Related Cancer · 01.07.2026 · 33 (7)

DOI: 10.1530/erc-25-0527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 18.06.2026. Verfasst von Federica Mangili und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy. Hauptthemen laut MEDLINE: Pituitary Neoplasms, RNA Splicing Factors, Prolactin, Prolactinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic mutations in the gene encoding splicing factor 3B subunit 1 (SF3B1), a key component of the splicing machinery, have been described in patients with PRL-secreting pituitary neuroendocrine tumors (PRL-PitNETs) and associated with aggressiveness and resistance to pharmacological therapy with dopamine agonists (DAs). Dopamine receptor type 2 (DRD2) represents the main target for PRL-PitNET treatment with DAs, even if about 10% of patients is resistant. The aims of the study were to i) test the effects of SF3B1 inhibitor pladienolide B in tumoral lactotroph cells expressing wild-type or mutated SF3B1R625H and ii) investigate the impact of SF3B1 on tumoral cells’ responsiveness to DRD2 agonist cabergoline. Pladienolide B treatment reduced cell proliferation (−45.1(15.3)%, P < 0.001) and PRL secretion (−19.25(35.1)%, P < 0.05) and increased apoptosis (+2.4(2.5)-fold, P < 0.05) in rat tumoral MMQ cells. The antimitotic, proapoptotic, and antisecretory effects of pladienolide B were maintained in primary cultured cells from both resistant and responsive PRL-PitNETs. SF3B1R625H overexpression increased tumoral lactotroph proliferation and migration. Moreover, the antimitotic efficacy of pladienolide B, but not of cabergoline, was maintained in MMQ cells transfected with SF3B1R625H. Cabergoline effects on cell proliferation, AKT activation, cyclin D3, and p27 were abolished in MMQ cells silenced for SF3B1. Accordingly, SF3B1R625H overexpression and SF3B1 silencing reduced DRD2 expression at both protein and transcript levels, an effect reverted by nonsense-mediated decay inhibitor NMDI14. In conclusion, we demonstrated a relevant role of SF3B1 in PRL-PitNETs. Indeed, SF3B1 inhibitor pladienolide B exerted antitumoral actions in PRL-PitNET cells bearing wild-type or mutated SF3B1. Moreover, both SF3B1R625H overexpression and SF3B1 genetic silencing reduced DRD2 expression and signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsRNA Splicing FactorsProlactinProlactinomaAnimalsRatsHumansApoptosisCell ProliferationMacrolidesReceptors, Dopamine D2Cyclin-Dependent Kinase Inhibitor p27Cyclin D3Cell Line, TumorDopamine AgonistsCell MovementFemaleEpoxy CompoundsPhosphoproteins

Stichwörter der Autor:innen

SF3B1 mutationDRD2PRL-secreting pituitary neuroendocrine tumorspladienolide Bsplicing machinery

Substanzen

RNA Splicing FactorsProlactinpladienolide BMacrolidesReceptors, Dopamine D2Cyclin-Dependent Kinase Inhibitor p27Cyclin D3SF3B1 protein, humanDopamine AgonistsEpoxy Compounds

Autor:innen und Institutionen

  • Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy.
  • Department of Clinical Sciences and Community Health, Department of Excellence 2023-2027, University of Milan , Milan, Italy.
  • Neurosurgery Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan , Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Italy.
  • Endocrinology and Diabetology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital , Rozzano, Italy.

ORCID-Profile: Federica Mangili, Donatella Treppiedi, Márta Korbonits, Erika Peverelli

Zitieren

APA

Mangili, F., Barbieri, A. M., Di Muro, G., Esposito, E., Treppiedi, D., Locatelli, M., Lania, A. G., Korbonits, M., Peverelli, E., & Mantovani, G. (2026). Characterization of SF3B1 role in prolactin-secreting pituitary tumors. Endocrine-Related Cancer, 33(7). https://doi.org/10.1530/erc-25-0527

Vancouver

Mangili F, Barbieri AM, Di Muro G, Esposito E, Treppiedi D, Locatelli M, et al. Characterization of SF3B1 role in prolactin-secreting pituitary tumors. Endocrine-Related Cancer. 2026;33(7). doi:10.1530/erc-25-0527

BibTeX
@article{Mangili2026,
  author = {Mangili, Federica and Barbieri, Anna Maria and Di Muro, Genesio and Esposito, Emanuela and Treppiedi, Donatella and Locatelli, Marco and Lania, Andrea G and Korbonits, Márta and Peverelli, Erika and Mantovani, Giovanna},
  title = {Characterization of SF3B1 role in prolactin-secreting pituitary tumors},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1530/erc-25-0527}
}
Kostenlos starten →